— Know what they know.
Not Investment Advice

UTHR NASDAQ

United Therapeutics Corporation
1W: -2.3% 1M: -3.6% 3M: -7.7% YTD: +5.4% 1Y: +71.9% 3Y: +110.8% 5Y: +183.7%
$523.63
-4.31 (-0.82%)
 
Weekly Expected Move ±3.0%
$496 $512 $528 $544 $560
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 39 · $22.2B mcap · 39M float · 1.22% daily turnover · Short 61% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$22.2B
52W Range272.12-609.35
Volume359,049
Avg Volume475,093
Beta0.58
Dividend
Analyst Ratings
17 Buy 12 Hold 1 Sell
Consensus Buy
Company Info
CEOMartine A. Rothblatt
Employees1,400
SectorHealthcare
IndustryBiotechnology
IPO Date1999-06-17
1040 Spring Street
Silver Spring, MD 20910
US
301 608 9292
About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Recent Insider Trades

NameTypeSharesPriceDate
ROTHBLATT MARTINE A M-Exempt 9,500 $135.42 2026-07-28
ROTHBLATT MARTINE A S-Sale 1,367 $523.15 2026-07-28
ROTHBLATT MARTINE A S-Sale 1,074 $524.04 2026-07-28
ROTHBLATT MARTINE A S-Sale 876 $525.02 2026-07-28
ROTHBLATT MARTINE A S-Sale 1,473 $526.34 2026-07-28

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms